Could Pharmacist Prescribing Grow In Wake Of Paxlovid Experience?
US FDA’s decision to allow pharmacists to prescribe Pfizer’s COVID-19 antiviral raises hopes and fears that the idea that could be applied more broadly post-pandemic.
You may also be interested in...
David Peacock, President, Asia Pacific, MSD tells Scrip how Lagevrio has gained dominance in certain parts of the world, though Paxlovid may have received the ‘lion’s share’ of public attention.
Giving prescribing authority to pharmacists could improve access to the antiviral for patients at high risk for severe COVID-19. Comirnaty financial outlook is also strengthened based on new US contract.
FDA’s “Additional Condition for Nonprescription Use” proposal is all about information which won’t be printed on DFLs but will be integral to whether some switch proposals’ approval. But agency doesn’t explicitly exclude switch sponsors from assigning delivery of ACNU information to staff in stores or in online chats.